文献速递皮肤肿瘤

实体器官移植中免疫抑制剂:皮肤不良反应与皮肤科考量

Immunosuppressive agents in solid organ transplantation: Cutaneous adverse effects and dermatologic considerations.
PubMed 文献 · J Am Acad Dermatol · 2026-03-27

实体器官移植受者因免疫抑制治疗进步而寿命延长,但慢性免疫抑制带来高负担的皮肤不良反应。本临床综述按药物类别(诱导剂、钙调神经磷酸酶抑制剂、抗代谢药、mTOR抑制剂、糖皮质激素、共刺激阻断剂)提供实用性概述,涵盖从早期超敏反应、脱发、口疮到光敏、伤口愈合受损及皮肤癌等迟发并发症。皮肤科医生在筛查、预防和管理中起核心作用,风险分层工具可指导转诊和监测时机,需与移植团队紧密协作以安全调整方案。

要点

  • 硫唑嘌呤和环孢素与皮肤鳞状细胞癌风险增加相关,mTOR抑制剂可能具有保护作用。
  • 皮肤不良反应范围从早期超敏反应、脱发、口疮到光敏、伤口愈合受损及皮肤癌。
  • 皮肤和紫外线肿瘤移植风险评估计算器等工具可指导皮肤科转诊和监测时机。

核心结论

  • 实体器官移植受者的慢性免疫抑制带来高负担皮肤不良反应,皮肤科医生在筛查、预防和管理中起核心作用。

研究设计与样本

  • 临床综述,按药物类别概述实体器官移植受者常用免疫抑制剂的皮肤毒性。

主要发现

  • 皮肤不良反应包括早期超敏反应、脱发、口疮、光敏、伤口愈合受损和皮肤癌。
  • 硫唑嘌呤和环孢素与皮肤鳞状细胞癌风险增加相关。
  • mTOR抑制剂可能提供保护益处。

关键数值与推荐

  • 皮肤和紫外线肿瘤移植风险评估计算器可指导皮肤科转诊和监测时机。

临床怎么用

  • 皮肤科医生应参与筛查、预防和管理皮肤毒性,并与移植团队紧密协作安全调整免疫抑制方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Solid organ transplant recipients are living longer due to advances in immunosuppressive therapy, but chronic immunosuppression carries a high burden of cutaneous adverse effects. This clinical review provides a practical, agent-specific overview of cutaneous toxicities associated with commonly used immunosuppressants in solid organ transplant recipients, including induction agents, calcineurin inhibitors, antimetabolites, mammalian target of rapamycin inhibitors, corticosteroids, and co-stimulation blockers. Cutaneous adverse effects range from early hypersensitivity reactions, alopecia, and aphthous ulcers to delayed complications such as photosensitivity, impaired wound healing, and skin cancers. Azathioprine and cyclosporine are associated with increased risk of cutaneous squamous cell carcinoma, while mammalian target of rapamycin inhibitors may offer protective benefits. Dermatologists play a central role in screening, prevention, and management of these toxicities. Risk stratification tools such as the skin and ultraviolet neoplasia transplant risk assessment calculator can guide timing of dermatologic referral and surveillance. Close collaboration with transplant teams is essential to adjust immunosuppressive regimens safely and minimize dermatologic morbidity while preserving graft function. This review aims to equip dermatologists with an updated framework for recognizing, managing, and preventing cutaneous adverse effects in this growing patient population.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Burke OM, Cabeza FH, Jaller JA, et al. Immunosuppressive agents in solid organ transplantation: Cutaneous adverse effects and dermatologic considerations. J Am Acad Dermatol. 2026. PMID: 41905624. doi:10.1016/j.jaad.2026.03.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。